MYRICX BIO
Live / Applied — Non-final action mailed (as of 26 Mar 2026)
What this means for you
Not registered yet, but its 06 Aug 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79442818
- Mark type
- Design + words
- Filed
- 06 Aug 2025
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biotechnological preparations; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs); antibody drug conjugates (ADCs) for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of proliferative human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging.
- Class 035 — Advertising and business services: Commercialisation of pharmaceuticals and biotechnological preparations; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; commercialisation of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors; consultancy, advisory and information services relating to the aforesaid services.
- Class 042 — Scientific and technological services: Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations; scientific and technological research, development and testing of pharmaceuticals and biotechnological preparations, including scientific and technological research for their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence, and diseases of aging, and scientific and technological research supporting their commercialisation; development and testing of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors; development and testing of antibody-drug conjugates (ADCs) and N- myristoyltransferase (NMT) inhibitors, and scientific and technological research supporting their commercialisation; consultancy, advisory and information services relating to the aforesaid services.
Owner
Prosecution history
- 26 Mar 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 26 Mar 2026 — REFUSAL PROCESSED BY MPU
- 21 Feb 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 20 Feb 2026 — NON-FINAL ACTION WRITTEN
- 07 Feb 2026 — ASSIGNED TO EXAMINER
- 06 Feb 2026 — APPLICATION FILING RECEIPT MAILED
- 06 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 05 Feb 2026 — SN ASSIGNED FOR SECT 66A APPL FROM IB